ewsba.se
Twist Bioscience Corporation (NASDAQ:TWST) is one of the best performing healthcare stocks so far in 2026. Twist Bioscience Corporation (NASDAQ:TWST) announced its fiscal Q2 2026 financial results and business highlights on May 4, reporting solid performance in the first half of 2026. It ended fiscal Q2 with its 13th consecutive quarter of growth, with total revenue for the quarter reaching $110.7 million, up 19% compared to $92.8 million for the same period last year. Cost of revenues for the quarter rose to $53.6 million, up from $46.8 million in fiscal Q2 2025, while gross margin increased to 51.6% compared to 49.6% for the prior year period.
Twist Bioscience Corporation (NASDAQ:TWST) further reported that research and development expenses for fiscal Q2 2025 decreased to $19.7 million compared to $23.9 million for the same period of fiscal 2025. The company shipped products to approximately 2,583 customers in the quarter, up from approximately 2,431 in the same period of fiscal 2025.
Twist Bioscience Corporation (NASDAQ:TWST) is involved in the development of a proprietary semiconductor-based synthetic DNA manufacturing process. The company’s operations are divided into the following geographical segments: Americas, EMEA, and APAC.
While we acknowledge the potential of TWST as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.
READ NEXT: 15 Stocks That Will Make You Rich in 10 Years AND 12 Best Stocks That Will Always Grow.
Disclosure: None. Follow Insider Monkey on Google News.